Biogen's Spinraza Sales Plateau; The Challenge Is Keeping Up With The Successful Launch
Sales of Biogen's blockbuster rare disease drug moderated in the first quarter as the company worked through the bolus of urgent infant and pediatric patients awaiting treatment in the US.
You may also be interested in...
Company highlighted recent pipeline advances in a variety of neuroscience indications during its third-quarter earnings report.
The company told its Q2 call it plans to talk to regulators about a filing strategy for the amyloid-targeting antibody based on Phase II data. Spinraza had a strong quarter, but Biogen’s SMA gene therapy is on clinical hold.
Key strategy updates are coming: GSK will unveil its new R&D approach, Biogen will update investors on its Alzheimer's plans, and investors are keen to find out whether or not Lilly will sell its animal health franchise. Investors will also be keeping an eye on how Gilead is faring with its move into oncology.